{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:14:07Z","timestamp":1762503247818,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ctro.2021.04.002","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T19:11:33Z","timestamp":1618945893000},"page":"124-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?"],"prefix":"10.1016","volume":"28","author":[{"given":"Jeffrey M.","family":"Ryckman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley N.","family":"Reames","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey A.","family":"Klute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Baine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2021.04.002_b0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12032-017-0951-0","article-title":"Neoadjuvant treatment in pancreatic cancer: evidence-based medicine? A systematic review and meta-analysis","volume":"34","author":"D\u2019Angelo","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0010","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update","volume":"37","author":"Khorana","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0015","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctro.2021.04.002_b0020","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: american society of clinical oncology clinical practice guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0025","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2021.04.002_b0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2021.04.002_b0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0040","article-title":"Detailed analysis of margin positivity and the site of local recurrence after pancreaticoduodenectomy","volume":"1\u201311","author":"McIntyre","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0045","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0050","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jama.291.9.1092","article-title":"Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial","volume":"291","author":"Wong","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2021.04.002_b0055","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-020-09460-z","article-title":"Neoadjuvant therapy for pancreatic ductal adenocarcinoma: propensity-matched analysis of postoperative complications using ACS-NSQIP","author":"Krell","year":"2021","journal-title":"Ann Surg Onc"},{"key":"10.1016\/j.ctro.2021.04.002_b0060","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","article-title":"Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma","volume":"154","author":"Maggino","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0070","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","author":"Truty","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.02.478","article-title":"A phase 1 dose Escalation study of neoadjuvant SBRT plus elective nodal radiation with concurrent capecitabine for resectable pancreatic cancer","author":"Witt","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2021.04.002_b0080","doi-asserted-by":"crossref","unstructured":"Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni SJIJoROBP. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97:313-22.","DOI":"10.1016\/j.ijrobp.2016.10.030"},{"key":"10.1016\/j.ctro.2021.04.002_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2020.01.012","article-title":"Dose-escalated radiation therapy for pancreatic cancer: a simultaneous integrated boost approach","author":"Koay","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2016.05.010","article-title":"A Phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458)","volume":"96","author":"Shaib","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2021.04.002_b0095","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","article-title":"The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience","volume":"22","author":"Moningi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0100","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","article-title":"Single-versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity","volume":"90","author":"Pollom","year":"2014","journal-title":"Int J Radiat Oncol Biol Physics"},{"key":"10.1016\/j.ctro.2021.04.002_b0105","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2021.04.002_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2019.01.075","article-title":"Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design","volume":"104","author":"Zhu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2021.04.002_b0115","article-title":"Australasian gastrointestinal trials group (AGITG) and trans-tasman radiation oncology group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT)","author":"Oar","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.adro.2018.07.008","article-title":"Dose escalation for locally advanced pancreatic cancer: how high can we go?","volume":"3","author":"Colbert","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600940","article-title":"Dosimetric feasibility study of dose escalated stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC) patients: it is time to raise the bar","volume":"10","author":"Mazzarotto","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0135","doi-asserted-by":"crossref","first-page":"465","DOI":"10.21873\/anticanres.13975","article-title":"Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: a multicentric analysis (PAULA-1)","volume":"40","author":"Arcelli","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctro.2021.04.002_b0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2018.11.002","article-title":"Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma","volume":"132","author":"Lin","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0145","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2010.04.058","article-title":"Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning","volume":"80","author":"Arvold","year":"2011","journal-title":"Int J Radiat Oncol Biol* Phys"},{"key":"10.1016\/j.ctro.2021.04.002_b0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2012.07.004","article-title":"Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning","volume":"104","author":"Qiu","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2012.11.019","article-title":"Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning","volume":"86","author":"Hall","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2021.04.002_b0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","article-title":"ESTRO ACROP guidelines for target volume definition in pancreatic cancer","volume":"154","author":"Brunner","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0170","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.prro.2018.06.006","article-title":"Incidence and patterns of locoregional failure after stereotactic body radiation therapy for pancreatic adenocarcinoma","volume":"9","author":"Baine","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.377","article-title":"Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas","volume":"39","author":"Katz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0180","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-020-09535-x","article-title":"Landmark series: neoadjuvant treatment in borderline resectable pancreatic cancer","author":"He","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0185","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0190","doi-asserted-by":"crossref","unstructured":"Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh RdW, Collisson E, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA surgery. 2016;151:e161137-e","DOI":"10.1001\/jamasurg.2016.1137"},{"key":"10.1016\/j.ctro.2021.04.002_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SLA.0000000000002672","article-title":"Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?","volume":"268","author":"He","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0200","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.2016.67.6049","article-title":"Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6)","volume":"34","author":"Lefevre","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0205","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COC.0000000000000278","article-title":"Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications","volume":"39","author":"Verma","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2019.07.004","article-title":"Phase 2 study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with gemcitabine for borderline resectable pancreatic adenocarcinoma (HOPS-BR 01)","volume":"105","author":"Hayashi","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2021.04.002_b0215","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","article-title":"Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer","volume":"258","author":"Takahashi","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0220","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial","volume":"16","author":"Garcia-Aguilar","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0225","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study","volume":"27","author":"Bujko","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2019.37.4_suppl.486","article-title":"Total neoadjuvant therapy with short course radiation compared to concurrent chemoradiation in rectal cancer","volume":"37","author":"Chapman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0235","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2020.38.15_suppl.4008","article-title":"Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial","volume":"38","author":"Garcia-Aguilar","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0240","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial","volume":"36","author":"Tienhoven","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0245","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0250","unstructured":"Peters GW, Hallemeier CL, Jethwa KR. Time to Reconsider Staging Laparoscopy in Pancreatic Cancer? Journal of Clinical Oncology.0:JCO.20.00996."},{"key":"10.1016\/j.ctro.2021.04.002_b0255","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejrad.2012.12.002","article-title":"An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment","volume":"82","author":"Cassinotto","year":"2013","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ctro.2021.04.002_b0260","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13566-013-0115-6","article-title":"Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships","volume":"2","author":"Dholakia","year":"2013","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.ctro.2021.04.002_b0265","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctro.2021.04.002_b0270","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2021.04.002_b0275","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/acm2.12528","article-title":"Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven DVH prediction model","volume":"20","author":"Nakamura","year":"2019","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ctro.2021.04.002_b0280","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Practical radiat Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630821000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630821000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:44Z","timestamp":1762502984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630821000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":56,"alternative-id":["S2405630821000392"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2021.04.002","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2021.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}